Alvotech’s Financial Calendar for 2026

Alvotech (NASDAQ: ALVO) published its 2026 financial calendar with scheduled dates for interim and annual results, investor calls and the annual general meeting.

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) published its 2026 financial calendar with scheduled dates for interim and annual results, investor calls and the annual general meeting. Results are released after U.S. market close and an investor call follows the next day.

• Mar 18, 2026 – Q4 2025 / full-year 2025 results
• May 6, 2026 – Q1 2026 results
• Jun 3, 2026 – Annual General Meeting (Luxembourg)
• Aug 19, 2026 – Q2 2026 / first six months
• Nov 11, 2026 – Q3 2026 / first nine months
• Mar 10, 2027 – Q4 2026 / full-year 2026

All dates are subject to change. Investor relations contacts were provided for follow-up.

Argus Dec 22 session

+0.82% close to close Open Argus

Details

News Market Reaction – ALVO

In the Dec 22 session, ALVO gained 0.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets out Alvotech’s 2026–2027 financial reporting and AGM schedule, specifying whe...

Analysis

This announcement sets out Alvotech’s 2026–2027 financial reporting and AGM schedule, specifying when quarterly and full-year results are planned and when investor calls occur. For investors tracking prior milestones—like recent biosimilar approvals, financing transactions and guidance updates—these dates mark key checkpoints for assessing execution progress and financial impact. Attention will likely focus on how revenue, EBITDA and launch timelines evolve across these scheduled reporting periods.

Key Figures

Q4 2025 & FY 2025 results date: March 18, 2026 Q1 2026 results date: May 6, 2026 Q2 2026 results date: August 19, 2026 +3 more

Q4 2025 & FY 2025 results date

March 18, 2026

Financial results release after U.S. market close

Q1 2026 results date

May 6, 2026

Quarterly financial release

Q2 2026 results date

August 19, 2026

First six months 2026 financials

Q3 2026 results date

November 11, 2026

First nine months 2026 financials

Q4 2026 & FY 2026 results date

March 10, 2027

Full-year 2026 financials

Annual General Meeting

June 3, 2026

AGM held in Luxembourg

Historical Context

5 past events · Latest: Dec 19

5 events

1. Dec 19

   Biosimilar settlement

   24h Move

   +3.6%

   Settlement with Regeneron enabling potential U.S. launch of AVT06.

2. Dec 17

   Convertible bond financing

   24h Move

   -0.8%

   USD 108M senior unsecured convertible bonds to fund R&D and launches.

3. Dec 16

   Financing and guidance

   24h Move

   -6.7%

   USD 100M bond launch plus detailed 2025–2026 revenue and EBITDA guidance.

4. Nov 24

   EU approval AVT03

   24h Move

   +6.4%

   European Commission approval of AVT03 denosumab biosimilar across EEA.

5. Nov 20

   EU approval Gobivaz

   24h Move

   -3.3%

   EEA marketing authorizations for Gobivaz®, a Simponi biosimilar.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the following day, after release of the results.

March 18, 2026: Q4 2025 – full-year 2025
May 6, 2026: Q1 2026
August 19, 2026: Q2 2026 – first six months
November 11, 2026: Q3 2026 – first nine months
March 10, 2027: Q4 2026 – full-year 2026
June 3, 2026: Annual General Meeting (held in Luxembourg)

Please note that all dates are subject to change.

Alvotech Investor Relations
Balaji Prasad (US)
Benedikt Stefánsson, VP (IS)
Patrik Ling, VP (SE)
alvotech.ir@alvotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Alvotech (ALVO) release its Q4 2025 and full-year 2025 results?

Alvotech plans to release Q4 2025 and full-year 2025 results on March 18, 2026 after U.S. market close.

On what date is Alvotech's (ALVO) Annual General Meeting in 2026?

The Annual General Meeting is scheduled for June 3, 2026 and will be held in Luxembourg.

When will Alvotech (ALVO) report Q1 2026 results and when is the investor call?

Q1 2026 results are scheduled for May 6, 2026 after market close, with an investor call the following day.

What are the dates for Alvotech's (ALVO) midyear and Q3 2026 reports?

Alvotech will report Q2/first six months on August 19, 2026 and Q3/first nine months on November 11, 2026.

Will Alvotech (ALVO) hold investor calls after each results release in 2026?

Yes. Each results release is followed by an investor call on the next day, per the published calendar.

Are Alvotech's (ALVO) 2026 financial calendar dates final?

No. The company notes that all dates are subject to change and investors should verify closer to each date.